Total Holdings
58
Portfolio diversification across 58 positions
CANC
(NASDAQ)Tema Oncology ETF
$37.11-- (--)
Loading... - Market loading
CANC ETF Holdings: Tema Oncology ETF
Complete portfolio holdings with allocation weights, sector breakdown, and geographic exposure for this Equity ETF. Analyze fund diversification and concentration.
Assets Under Management
$150.52M
Total fund assets
Expense Ratio
0.75%
Annual management fee
Fund Issuer
Tema
NASDAQ
Portfolio Allocations
Distribution breakdown by sector, asset type, and geographic region. Understand the fund's diversification strategy across markets and asset classes.
Loading chart...
Top 50 Holdings by Portfolio Weight
View ticker symbols, company names, asset types, and allocation percentages for each position
Scroll to see more
| # | Symbol | Name | Type | Weight |
|---|---|---|---|---|
| 1 |  | Revolution Medicines, Inc | Stock | 6.35% |
| 2 |  | Eli Lilly and Company | Stock | 5.03% |
| 3 | S SWX:NOVN | Novartis AG | Stock | 4.63% |
| 4 |  | BridgeBio Pharma, Inc. | Stock | 4.42% |
| 5 | L LSE:AZN | AstraZeneca PLC | Stock | 4.38% |
| 6 | L LON:AZN | AstraZeneca PLC | Stock | 4.32% |
| 7 | O OTC:RHHBY | Roche Holding AG | Stock | 4.30% |
| 8 | O OTCQX:RHHBY | Roche Holding AG | Stock | 4.21% |
| 9 |  | Bristol-Myers Squibb Company | Stock | 4.05% |
| 10 |  | Genmab A/S | Stock | 3.83% |
| 11 |  | Merck & Co., Inc. | Stock | 3.81% |
| 12 |  | Nuvalent Inc | Stock | 3.48% |
| 13 |  | Exelixis, Inc | Stock | 3.37% |
| 14 |  | Cogent Biosciences, Inc. | Stock | 3.24% |
| 15 |  | Immunome, Inc. | Stock | 3.12% |
| 16 |  | Johnson & Johnson | Stock | 3.03% |
| 17 |  | AbbVie Inc | Stock | 2.87% |
| 18 |  | Amgen Inc. | Stock | 2.65% |
| 19 |  | Celcuity LLC | Stock | 2.56% |
| 20 |  | Arcellx, Inc. | Stock | 2.44% |
| 21 | B BGNE | BeiGene, Ltd | Stock | 2.27% |
| 22 |  | Ideaya Biosciences Inc | Stock | 2.19% |
| 23 |  | BeOne Medicines AG | Stock | 2.05% |
| 24 |  | Nuvation Bio Inc | Stock | 2.00% |
| 25 |  | Gilead Sciences, Inc | Stock | 1.98% |
| 26 |  | Syndax Pharmaceuticals Inc | Stock | 1.97% |
| 27 |  | Legend Biotech Corporation | Stock | 1.91% |
| 28 |  | CG Oncology, Inc. | Stock | 1.55% |
| 29 |  | Summit Therapeutics PLC | Stock | 1.53% |
| 30 |  | Halozyme Therapeutics, Inc. | Stock | 1.51% |
| 31 |  | Zymeworks Inc. | Stock | 1.45% |
| 32 |  | Regeneron Pharmaceuticals, Inc | Stock | 1.34% |
| 33 |  | Zai Lab Limited | Stock | 1.26% |
| 34 |  | Nurix Therapeutics, Inc | Stock | 1.21% |
| 35 |  | UroGen Pharma Ltd | Stock | 1.20% |
| 36 |  | argenx NV ADR | Stock | 1.09% |
| 37 |  | Olema Pharmaceuticals Inc | Stock | 1.05% |
| 38 | T TSE:4568 | Daiichi Sankyo Co. Ltd. | Stock | 1.04% |
| 39 |  | Enliven Therapeutics Inc. | Stock | 0.91% |
| 40 |  | Xencor, Inc | Stock | 0.91% |
| 41 |  | AnaptysBio, Inc | Stock | 0.87% |
| 42 | T TSE:4519 | Chugai Pharmaceutical Co. Ltd. | Stock | 0.86% |
| 43 |  | Immunocore Holdings plc | Stock | 0.86% |
| 44 |  | Arcus Biosciences, Inc | Stock | 0.80% |
| 45 |  | Relay Therapeutics, Inc | Stock | 0.75% |
| 46 |  | Guardant Health, Inc | Stock | 0.70% |
| 47 |  | Janux Therapeutics Inc | Stock | 0.66% |
| 48 |  | HUTCHMED (China) Limited | Stock | 0.60% |
| 49 |  | Corvus Pharmaceuticals Inc | Stock | 0.54% |
| 50 |  | Replimune Group Inc | Stock | 0.47% |